CeloNova Biosciences Receives FDA Approval of Nanocoating COBRA PzF™ Stent System


CeloNova BioSciences, Inc. (CeloNova) announced that it has received U.S. Food and Drug Administration (FDA) approval of its first-in-class COBRA PzF™ NanoCoated Coronary Stent System. Regulatory approval of the novel stent system was based on findings from the pivotal PzF SHIELD clinical trial, which successfully met its primary safety and effectiveness endpoints at 9-month follow-up,


You need to be a subscriber to Nanotech Magazine to view this page. If you are a member please log-in, if you are not and wish to view this content please go to https://www.nanotechmag.com/plans/subscription/